Lexaria Bioscience Corp. LXRP Archives - Page 26 of 27

TuesdayAug 29, 2017 9:34 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Scheduled to Attend Two Cannabis Conferences in September

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a company engaged in licensing proprietary technology for the delivery of bioactive compounds, this morning announced its plans to attend two cannabis investment conferences in September. The first, the Investorshub International Cannabis Conference, will be held at the JW Marriott in downtown Los Angeles on September 1-2. The second, the Institutional Capital & Cannabis Conference (East), is scheduled to take place on September 7-8 in Miami Beach. This morning’s news release also included an update on the company’s financing activities. Notably, Lexaria has received and executed a notice of conversion related to certain…

FridayAug 25, 2017 11:51 am

QualityStocksNewsBreaks – Disruptive Process Pioneered by Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Creates Superior Cannabis Edibles

Common complaints among consumers of cannabis edibles include the presence an unpleasant taste, but this and other inadequacies are being overcome through the innovations of Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP). Lexaria’s disruptive process masks the unpleasant taste of cannabis, and the company’s lipophilic enhancement technology also changes the way cannabinoids enter the body while significantly speeding up the timeframe in which THC’s effects are felt and increasing bio-absorption by as much as tenfold. As noted in a recent NNW article: “Because cannabinoids are absorbed poorly by the gastrointestinal tract, many cannabis users turn to other administration routes, like…

FridayAug 25, 2017 9:21 am

Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) Revolutionary Process Creates Superior Cannabinoid Edibles

19 patent applications filed in the United States and internationally (under the Patent Cooperation Treaty), with national filings in 44 countries Collaborative research and development agreement with Canada’s National Research Council to investigate opportunities associated with bioavailability enhancement of certain compounds, including those in cannabinoids, vitamins, NSAIDs and nicotine Out-licenses its patented technology to third party partners, with several deals signed or pending When Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) researchers tackled the issue facing consumers of edible cannabinoids – poor absorption of the product’s bioactive compounds by the body’s gastrointestinal tract – an important statement led the way:…

ThursdayAug 17, 2017 3:03 pm

Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) Revolutionary Process Creates Superior Cannabinoid Edibles

Disruptive, patented technology is set to revolutionize the edible cannabis market Company has patent applications in 45 countries, including 18 applications in the U.S. Technology is patent-protected for CBD and all other non-psychoactive cannabinoids, with patents pending for THC, other psychoactive cannabinoids, NSAIDs, nicotine and other molecules A common complaint among the consumers of cannabis edibles is an unpleasant taste that can often be detected, but that unpleasant taste and other inadequacies of cannabis edibles are being overcome thanks to the incredible innovations of Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP). Lexaria is literally bringing new flavor to the marijuana…

MondayAug 14, 2017 11:39 am

Regulation Forcing Drug and Cigarette Companies to Be More Responsible is Great News for Lexaria (LXRP), says CEO

In an interview with Stock Day, CEO Chris Bunka of Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) discussed the company’s recent achievements and its plans for the near future. Revenues are climbing, exceeding, so far in 2017, the total for all of 2016, and the potential for further increases is imminent. The company is in negotiation with at least four large pharmaceutical companies to license its technology. The smallest of these could increase revenues by $1 million; the largest could increase revenues by much, much more, according to Bunka. Getting any of these deals signed will boost the bottom line…

ThursdayAug 10, 2017 9:35 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) CEO Discusses Company’s Progress in Interview

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a company engaged in licensing proprietary technology for the delivery of bioactive compounds, this morning announced that its chief executive officer, Chris Bunka, was featured in a recent interview on the Uptick Network Stock Day Radio Show. Bunka leveraged the platform to discuss Lexaria’s overall accomplishments in the past three months, as well as the company’s expectations for profitability moving forward. He notes that ongoing research and development programs could open both the NSAID and Nicotine markets to Lexaria, providing an opportunity to significantly increase corporate revenues and facilitate further expansion. “In the…

TuesdayAug 08, 2017 4:06 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Praised in Technical420 Article

Lexaria Bioscience Corp. featured in a Technical420 article praising the company’s recent developments Lexaria is improving and strengthening patent portfolio; 19 patent applications are pending in more than 40 countries Company executes partnership with NeutriSci International; joint venture allows LXRP to enter Asian market Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), an innovative company licensing proprietary technology for the delivery of bioactive compounds including cannabinoids, is a “plant-to-bloodstream” company expected to draw investors in the cannabis marketplace. Lexaria has patented and licenses a novel delivery system that infuses organically sourced hemp oil into the molecules of other substances. Cannabidiol, noted…

ThursdayAug 03, 2017 9:37 am

Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) Technology Offers More Potent Delivery of Cannabinoids

Technology that improves bioavailability of orally ingested cannabinoids Safer approach that mitigates risks from carcinogens Generates revenue by out-licensing its technology internationally Announcement of a new government initiative to reduce the level of nicotine in cigarettes to nonaddictive levels is good news for Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP). Less addictive cigarettes mean less dependence on smoking as a delivery system, not only for nicotine but other substances like cannabinoids, which is why the folks at Lexaria are cheering the Food and Drug Administration (FDA) on. This innovative bioscience company has developed technology that offers a safer and more efficient…

WednesdayAug 02, 2017 3:27 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Spotlighted by Technical420

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a company engaged in licensing proprietary technology for the delivery of bioactive compounds, including cannabinoids, was recently spotlighted in an article on Technical420.com. The publication highlighted, in detail, several of the company’s key developments and growth catalysts. “During the last few months, Lexaria has improved its fundamental story through the following developments: 1) The company applied for a new patent from the U.S., 2) Lexaria has advanced its agreements and launched new businesses, 3) Expands its Reach into Asia, 4) Focused on R&D with major organizations, and 5) The company’s cash position has…

TuesdayAug 01, 2017 1:09 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Sees New Round of Investors Attracted to Cannabis Market

Has patents in the United States and Australia and patents pending in more than 40 countries for proprietary technology easing how edible cannabinoids enter body Revenue stream comes from own products and 5-10% margin of gross sales from licensing technology to third parties Signed C$250,000 joint venture agreement with National Research Council (NRC) in Canada to research and find best methods for processing active agents in foods Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) already owns international patents for its proprietary intellectual property and has more global patents pending in the cannabis marketplace. It believes that the sub-sector of bioscience…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LXRP

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Scheduled to Attend Two Cannabis Conferences in September

QualityStocksNewsBreaks – Disruptive Process Pioneered by Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Creates Superior Cannabis Edibles

Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) Revolutionary Process Creates Superior Cannabinoid Edibles

Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) Revolutionary Process Creates Superior Cannabinoid Edibles

Regulation Forcing Drug and Cigarette Companies to Be More Responsible is Great News for Lexaria (LXRP), says CEO

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) CEO Discusses Company’s Progress in Interview

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Praised in Technical420 Article

Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) Technology Offers More Potent Delivery of Cannabinoids

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Spotlighted by Technical420

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Sees New Round of Investors Attracted to Cannabis Market

Market Basics

Newsletter Publishers

Public Companies